Keros lists Phase 2 trial of KER-065 in Duchenne muscular dystrophy on ClinicalTrials.gov

Keros Therapeutics had one clinical trial item on the registry this week.

• Keros Therapeutics is evaluating KER-065, also known as Rinvatercept, in a Phase 2 open-label study of adult and pediatric ambulatory and nonambulatory male participants with Duchenne Muscular Dystrophy on stable background therapy.¹ The study is listed as not yet recruiting, with an estimated start date of September 14, 2026 and estimated enrollment of 36 participants across three treatment cohorts, including two late ambulatory cohorts and one early nonambulatory cohort.¹ The primary outcome is the number of participants with treatment-emergent adverse events and serious adverse events over roughly 14 months, evaluating the safety and tolerability of KER-065 in ambulatory and nonambulatory participants with DMD.¹